




**4th World Congress of the
International Society for Apheresis**

**Thursday, October 30 – Saturday,
November 1, 2003**

**Gaylord Opryland Resort
and Convention Center
Nashville, Tennessee, USA**

Program

(Last Updated 08/Oct/03)



Sessions at a Glance

	Thursday October 30, 2003	Friday October 31, 2003	Saturday November 1, 2003
0800-1000	Opening Ceremony Governor Ballroom C	Plenary Sessions Governor Ballroom C	LDL-Apheresis II Governor Ballroom C
1000-1030	Refreshment Break Governor's Ballroom D		
1030-1200	Immunoadsorption Governor Ballroom C	LDL-Apheresis I Governor Ballroom C	Hematology Governor Chamber D
1200-1400	Lunch Break (1200-1400)	Lunch Break (1200-1400)	Plenary Session Closing Ceremony Governor Ballroom C
		Editorial Board (1300-1400) President Ballroom A	
1400-1530	Cell Separation Governor Ballroom C	WAA Board (1200-1300) President Ballroom A	ISFA General Assembly (1300-1400) Governor Ballroom C
		Apheresis Technologies Governor Ballroom C	
1530-1600	Refreshment Break Governor's Ballroom D		
1600-1730	Therapeutic Apheresis Governor Ballroom C	Critical Care/ Sepsis Governor Ballroom C	

Arrangements have been made with Vanderbilt University School of Medicine in Nashville, Tennessee to provide Continuing Medical Education(CME) for physicians and Continuing Education Units (CEU) for nurses. Details will be provided at the Registration Desk

WEDNESDAY OCTOBER 29, 2003

1200 - 1700	Exhibitor Set-Up in Exhibitor Hall - Governor's Ballroom D
1300 - 1600	Congress Registration - Governor's Registration Desk
1500 - 1700	Photopheresis Workshop - Bayou A Sponsored by Therakos
1700 - 1800	ISFA Board Member Meeting I - [Board Members Only] - President Boardroom A
1800 - 2000	Welcome Reception [Open to all Registered Participants] - Governor's Ballroom C

THURSDAY, OCTOBER 30, 2003

0700-1600	Speaker Ready Room - Governor's Chamber A
0800-1200	On-site Registration - Governor's Registration Desk
0800 - 1000	Opening Ceremony/ Plenary Session - Governor's Ballroom C Plenary Session Chairs: Masashi Kodama, MD and Paul Malchesky, DEng Opening Remarks - Ghodrati Siami, MD, PhD, Congress President Opening Remarks - Paul S. Malchesky, DEng, ISFA President Opening Remarks - Peter Ivanovich, MD, WAA President Blood Purification in the 21st Century - Yukihiko Nosé, MD, PhD State of the Art of LDL, Apheresis in the year 2003 - Thomas Bosch, MD (#51) State of Art Lecture on Immunoadsorption - Horst Klinkmann, MD, PhD
1000-1030	Refreshment Break/ Poster Session (Exhibit Hall) - Governor's Ballroom D
1030 - 1200	Immunoadsorption - Governor's Ballroom C Chairs: Leonel Szteling, MD and Kurt Derfler, MD Griveas, I (#31): Immunoadsorption in lupus myocarditis

Pokrovsky, S (#35): The long term observation of patients with dilated cardiomyopathy treated by immunoadsorption with Ig-Adsopak columns

Rummier, S (#43): Severe Sharp Syndrome with Pulmonary Manifestation: Experiences with Immunoadsorption

Tsushima, K (#10): The endotoxin adsorption therapy (PMX-DHP) is effective for hydrochloric acid-induced lung injury in rat

1200 - 1400
1300 - 1400

Lunch Break - Enjoy Restaurants in Opryland
Editorial Board Meeting for Therapeutic Apheresis & Dialysis - President Ballroom A

1400 - 1530

Cell separation - Governor's Ballroom C
Chairs: Ramakrishna Reddy, MD and Jerard Seghatchian, PhD

Seghatchian, J (#30): Standardization/Harmonization in blood component technology update on universal leukoreduction

Horie, T (#41): Therapeutic angiogenesis using peripheral blood stem cells

Omokawa, S (#49): Comparative evaluation of efficacy in platelet collection using three apheresis systems and status of platelet transfusion

McCarthy, LM (#76): RBC Exchange Experience

Heard, K (#23): Relationship between Pre CD34 & Product CD34 in PBSC collections

Reddy, R (#73): Improvement in Blood Prime for Pediatric Procedures on COBE Spectra

1530 - 1600

Refreshment Break/ Poster Session (Exhibit Hall) - Governor's Ballroom D

1600 - 1730

Therapeutic Apheresis - Governor's Ballroom C
Chairs: Andre Kaplan, MD and Sergio Stefoni, MD

Szpit, W (#77) - The update on PE in vasculitis treatment

Kim, S (#69): Tandem Cryofiltration Apheresis and Hemodialysis in 3 Patients with Hepatitis C Associated Cryoglobulinemia and Renal Failure

Visvardis, G (#32): Therapeutic apheresis of immune diseases in nephrology dept.

Ferrannini, M (#54): Cascade Filtration (CF) in cryoglobulinemic renal damage

Norda, R (#48): Therapeutic apheresis in Sweden: update of epidemiology and adverse events

Srivastava, R (#19): Comparative analysis of different apheresis technologies in India

1830-2030

Presidential Dinner [Invitation Only] - Delta Island E

0800-1730

Poster Session (Exhibit Hall) - Governor's Ballroom D

Rummier, S (#3): Protein A-Immunoabsorption (PA-IA): Anticoagulation with Heparin
 Maruoka, H (#11): Treatment of Plasmapheresis Improved a patient with Thrombotic Thrombocytopenic Purpura (TTP) accompanied with systemic lupus erythematosus (SLE)
 Bartram, M (#16): Intercept platelets treated for pathogen inactivation from Haemonetics MCS+ and Cobe Spectra System are similar to Amicus separator and met AAB standards
 Bartram, M (#66): Intercept platelets for pathogen inactivation from Trima collection system are similar to Amicus separator and meet AAB standards
 Matsuda, Y (#17): Double filtration plasmapheresis (DFPP) for the treatment of a rheumatoid arthritis (RA) patient with extremely high level of C-reactive protein (CRP)
 Kim, SD (#24): Fatigue related to peripheral blood stem cell collection in leukemia patients
 Kim, SD (#25): Effects of distraction on needle pain and anxiety from venipuncture in platelet donors
 Burkhardt, T (#27): Measurement of quality of FFP in Consideration of possible immunization of patients by WBC or PTL Antigens
 Nitta, Y (#29): Prediction of the hematocrit value using an artificial neural network during leukocytapheresis therapy
 Vattuone, T (#78): Successful Cyto reduction in a 5-month old Infant with Extreme Hyperleukocytic ALL (T cell type)
 Heinrich HW (#83): Personalized Therapy of SEPSIS – The Modular Immune Adsorber System (MIAS)
 Heinrich HW (#84): Personalized Therapy of Chronic Dysfunctions of the Immune System – The Patient Specific Immune Adsorber (PSIA).

1/2 Day Spouse Program/ Tour

FRIDAY, OCTOBER 31, 2003

0700 - 1600 **Speaker Ready Room - Governor's Chamber A**

0800 - 1200 **On-site Registration - Governor's Registration Desk**

0800 - 1000 **Plenary Session - Governor's Ballroom C**
Chairs: Paul Malchesky, Deng and John Zic, MD

Where therapeutic apheresis comes from and where is it going - Tetsuzo Agishi, MD
 Artificial Liver Support: An Update - Achilles Demetrou, MD, PhD

Photopheresis Plenary (Sponsored in part by Therakos)

Extracorporeal Photopheresis in the treatment and prevention of Graft-vs-Host Disease - Francine M Foss, MD (#56)
 Photopheresis in the treatment of cutaneous T Cell Lymphoma - John Zic, MD (#57)
 Transimmunation: patient-specific anti-tumor immunotherapy - Richard Edelson, MD (#55)

1000 - 1030 **Refreshment Break/ Poster Session (Exhibit Hall) - Governor's Ballroom D**

1030 - 1200 **LDL-apheresis I - Governor's Ballroom C**
Chairs: Rolf Bamberger, MD and Akira Yamamoto, MD, PhD

Bosch T (#50): Efficacy & safety of Dali LDL-Apheresis at high blood flow rates: A multicenter study
 Bosch, T (#52): Modified Dali LDL-Apheresis using Trisodium Citrate Anticoagulation plus Bicarbonate or Lactate-Buffered Hemofiltration Substitution Fluids as Primers
 Pokrovsky, S (#34): Lipids apheresis by immunosorbents is the effective method for LDL and Lp(a) elimination
 Pokrovsky, S (#33): Lipoprotein (a) apheresis by specific immunoadsorption is the single way for effective treatment of severe CHD patients with elevated Lp(a) level.

Hematology/ Microangiopathy - Governor's Chamber D
Chairs: Leo McCarthy, MD and Hiroshi Tsuda, MD

McCarthy, LM (#28): TTP: Yesterday, Today, and the Future.
 Kiprov, D (#74): Increasing incidence of TTP/HUS
 Chiu, HC (#2): Clearance of fibrinogen and von willebrand factor in serial double-filtration plasmapheresis
 Reddy, R (#20): Complication of Hemolysis due to mechanical reasons during therapeutic plasma exchange - A case report

Bambauer, R (#81): Low-density Lipoprotein Apheresis: An Overview and Clinical Results
 Schuff-Werner P (#82): Long-term H.E.L.P.-Apheresis: Clinical Outcome and Safety in 628 Patients

Shiga, H (#13): Continuous Hemodiafiltration (CHDF) for hypercytokinemia in tumor lysis syndrome (TLS)

1200 - 1400 Lunch Break - Enjoy restaurants in Opryland
1200 - 1300 WAA Board Meeting - President Boardroom A (lunch provided)
1300 - 1400 General Assembly - ISFA Members - Governor's Ballroom C

1400 - 1530 Apheresis Technology - Governor's Ballroom C
 Chairs: Akinori Sueoka, PhD and Anna Koo, MD

Leukocytapheresis - Governor's Chamber D
 Chairs: TBA

Storr, M (#63): Use of a Novel Functionalized Hollow Fiber Plasma Filtration Membrane for Removal of Toxins from Human Blood

Sawada, K (#72): Multicenter, randomized, double blind, controlled trial for ulcerative colitis therapy with leukocytapheresis

Siarni, FS (#61): Cryofiltration apheresis twelve years experience

Miyamoto, H (#15): Variation of the hematocrit value during leukocytapheresis therapy

Okahisa T (#26): Monitoring Filter clogging by analyzing the conductive condition of the roller pump flow pressure wave

Sakata, H (#1): Successful Treatment of Ulcerative Colitis with Leukocytapheresis Using Non-woven Polyester Filter

Wiese, F (#45): Membrane Technology-An important tool for therapeutic plasma treatment

Soerenson H (#85): Granulocyte and monocyte apheresis ADACOLUMN in SLE patients - Single center results of a pilot trial

Deupree, D (#64): Randomized Prospective Trial Investigating the safety and efficacy of membrane differential filtration apheresis (MDF) for the treatment of pre-angiogenic age-related macular degeneration

Okubu, H (#65): Plasma Fractionation Therapy on various diseases: Review of published data

1530 - 1600 Refreshment Break/ Poster Session (Exhibit Hall) - Governor's Ballroom D

1600 - 1730 Critical Care/ Sepsis/ Liver Support - Governor's Ballroom C
 Chairs: HiroYuki Hirasawa, MD, PhD and Stephen Ash, MD

Ash, S (#75): Overview of Sorbent-Based Pheresis in Treatment of Sepsis and/or Liver Failure

Kanesaka, S (#42): Effect of direct hemoperfusion B immobilized fiber on peripheral perfusion in patients with severe sepsis and septic shock
Stegmayr, B (#46): Can apheresis be one of the new approaches to treat severe septic shock and multiorgan dysfunction syndrome?
Hirasawa, H (#21): Efficacy of continuous hemodiafiltration in the treatment of severe acute pancreatitis
Sandeman, S (#44): A novel carbon device for the treatment of sepsis
Hanasaawa, K (#67): Outcome of Septic and Non Septic MOF Patients Treated with PMX DHP

1730 - 1830

ISFA Board Member Meeting II - [Board Members Only] - President Boardroom A

1900 - 2200

Farewell Dinner [reservations/payment required] - General Jackson Showboat

0800 - 1730

Poster Sessions (Exhibit Hall) - Governor's Ballroom D

Kobayashi, T (#4): a case of complete remission of minimal change nephrotic syndrome by apheresis monotherapy
Okazawa, K (#5): Assessment of digoxin adsorption by B2 microglobulin adsorbent (Lixelle)
Yeh, JH (#6): Plasmapheresis for hyperlipidemic pancreatitis
Lin, KJ (#8): Membrane characteristics in cytokine and endotoxin plasma level in hemodialysis patients
Abe, T (#12): The use of continuous albumin purification system (CAPS) in multiple organ failure (MOF)
Abe, T (#14): Plasma exchange (PE) in hepatic failure (HF): PE alone is unsafe and should be associated with HD in series
Amoureux, MC (#37): Endotoxin removal from human plasma and blood by a hemocompatible, affinity-based extracorporeal technology for the treatment of sepsis
Shinji, S (#53): Granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis suppresses the activation of NF-KB and release of granulocyte elastase via modification of leukocyte function
Endo, Y (#58): The relation between the clinical and plasma parameters and the changes in plasma endotoxin with PMX treatment
Mori, T (#59): Two cases of acute hepatic insufficiency treated with novel plasmapheresis plasma dia-filtration (PDF)
Tabata, T (#60): application of PMX treatment and CHDF for septic children
Kawakami, M (#62): Anandamide removal by polymyxin B immobilized column in septic shock patients
Hanasaawa, K (#68): Endotoxin removal and immune stimulation improve survival from gram-negative sepsis with PMX-DHP

1/2 Day Spouse Program/ Tour

SATURDAY, NOVEMBER 1, 2003

0700 - 1030 Speaker Ready Room - Governor's Chamber A

0800 - 1000 LDL-apheresis II - Governor's Ballroom C
Chairs: Mooto Tsushima, MD & Nobuhiko Koga, MD

Kawashima, A (#70): A new method of DFPP for LDL apheresis
Koga, N (#18): Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolemic patients
Tasaki, H (#9): Improvement in function & angiographic finding of coronary artery disease by LDL apheresis
Higashikata, T (#40): therapeutic effects of LDL apheresis on coronary heart disease in patients with familial hypercholesterolemia
Shiba, MH (#7): Long term effect of LDL apheresis on homozygous FH patients
Tshushima, M (#36): Long term effects of LDL apheresis atherosclerosis in FH patients

1000 - 1030 Refreshment Break (Exhibit Hall) - Governor's Ballroom D

1030 - 1200 Plenary Session - Governor's Ballroom C
Chairs: Akira Yamamoto, MD and Horst Klinckmann, MD, PhD

Update on Clinical Trials - Wolfgang Ranzow, MD
WAA Registry - Bernd Stegmayr, MD (#47)
International Registry - Paul S. Malchesky, DEng (#22)
Closing Ceremony

1030 - 1600 Exhibitor Breakdown - Governor's Ballroom D



Commercial Exhibition

The following companies will exhibit products in the Exhibition Area at the 4th World Congress of the International Society for Apheresis.

ASFA

American Society for Apheresis

AMERICAN SOCIETY FOR APHERESIS - ASFA (Tucson, AZ, USA) is dedicated to meeting the diverse needs of apheresis practitioners for training, continuing education and scholarly interaction. The central purpose of ASFA is to bring together a wide range of apheresis practitioners for sharing of ideas and experience, critical evaluation of emerging information and collaboration in research. Through meetings, publications and personal interactions, society members work together toward the betterment of patient care with apheresis technology.

B. BRAUN

B. Braun Medical, Inc. (Bethlehem, PA, USA) is dedicated to helping you achieve excellence in safety through our People, Products, and Programs. We are committed to delivering innovative safety products and programs with unmatched quality, superior technology, and cost-effective solutions, while maintaining environmental responsibility. For more than 160 years, our tradition of expertise and progress has set a clear example of excellence in the global marketplace. With more than 28,000 employees worldwide, B. Braun is a full line IV therapy and healthcare products supplier. Our professionalism, integrity, and high level of service are recognized daily by our customers. B. Braun continues to set new standards of care through our product development, promoting best practices with the continuous improvement of safety. As a leading safety company in health care, we believe that our total commitment to achieving excellence in safety is critical to your success.

GAMPRO

Gampro BCT (Lakewood, CO, USA) is a frontrunner in the blood bank technology industry. Our Trima system is the first automated blood collection system to collect a combination of leukoreduced red blood cells, platelets and plasma, helping blood centers be more efficient than ever before. We are further expanding our leadership role in the therapeutic apheresis and cell therapy arenas, with the development of strategic alliances targeting cancer therapies and cancer vaccine development. Plus, in the spirit of innovation and leadership, we are currently developing exciting new technology in the field of pathogen inactivation.


КАНЕКА

Kaneka Pharma America Corporation (New York, NY, USA) is a wholly owned subsidiary of Kaneka Corporation. We are the exclusive distributor of the Liposorber System in the United States. Kaneka Corporation, located in Japan, is a producer of chemicals, resins, plastics, food products, pharmaceuticals intermediates, synthetic fibers and electrical materials. Kaneka's family of companies spans 14 countries in North America, Europe and Asia. Kaneka products are sold in more than 100 countries.

THERAKOS

a Johnson & Johnson Company

THERAKOS, a Johnson & Johnson Company, (Exton, PA, USA), was established to foster advances in the extracorporeal management of disease. We have taken a leadership role in intensive research in photoimmune therapy. This research has led to the development of Photopheresis, a revolutionary new approach to the management of disease using photoactivatable agents and light. Our UVAR® Photopheresis System and our UVAR® XTS™ System are approved for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL), a malignancy of T cells that invades the skin.



Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy, and publishes original articles on basic through advanced apheresis technologies and treatments, editorial comments, review articles, case reports, meeting abstracts and Communications information.